TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03855410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S4E
Description: The face-to-face version of S4E (i.e., Storytelling for Empowerment) is registered as a best-practice with the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-Based Practices and Programs.The S4E mHealth app was developed in collaboration with youth in Southeast Michigan. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol and drug use, HIV and STIs. We now propose to develop modules focused on tobacco prevention and cessation. S4E aims to increase self-efficacy and communication about health risk behaviors. The face-to-face version of S4E has been shown to prevent and reduce substance use, including cigarette use, as well as increase (1) substance use prevention knowledge, (2) communication about health risk behaviors, and (3) perception of harm and self-efficacy in refusing licit and illicit substances.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention-Matched Control Group
Description: Participants in the Attention-Matched Control group will receive a PDF version of the tobacco module material, an enhancement to the usual care they would receive should they not join the study. Participants in this group will also receive usual care. The Clinic's usual care includes standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services.
Study: NCT01035333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: 60mg capsule three times a day for up to 6 months
Study: NCT01333540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Escalating doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT01376960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective forefoot surgery
Description: Includes both soft-tissue and osseous procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective forefoot surgery
Description: Includes both soft-tissue and osseous procedures.
Study: NCT02123615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Study: NCT00451555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily
Study: NCT01950104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 3 embryo biopsy
Description: Embryo biopsy is applied at day 3 of the embryo development.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blastocyst biopsy
Description: Embryo biopsy is applied at the blastocyst stage of the embryo development
Study: NCT00992628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh (direct vision) laryngoscope
Description: Macintosh (direct vision) laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope videolaryngoscope (indirect vision)
Description: GlideScope videolaryngoscope (indirect vision)
Study: NCT04514640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Calm app
Description: All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Calm app
Description: All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Calm app
Description: All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention.
Study: NCT00510016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine HCL
Description: Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
Study: NCT03326817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients receive standard care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Robotic Glove Group
Description: This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
Study: NCT01844115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Viibryd
Study: NCT02300285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
Study: NCT00451555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fulvestrant
Description: 500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
Study: NCT02840175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
Study: NCT02300285

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
Study: NCT01070823

Intervention type: DRUG
Intervention: Tysabri® (natalizumab)
Description: Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
Study: NCT02084719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oraquick HCV Rapid Antibody Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard algorithm
Study: NCT03305224

Intervention type: DRUG
Group type: OTHER
Intervention: Ra-223 in combination with enzalutamide
Description: Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
Study: NCT01197820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96\*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128\*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed
Study: NCT01380990

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of autologous EFS-ADA LV CD34+ cells
Description: Autologous EFS-ADA LV CD34+ cells (OTL-101\*) are infused intravenously

Intervention type: OTHER
Group type: OTHER
Intervention: Haematopoietic Stem Cell Transplantation (HSCT)
Description: Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is used for non-myeloablative conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Ada
Description: Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
Study: NCT01229982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Punctal Plug
Study: NCT04848181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyproterone acetate
Description: two weeks Cyproterone acetate administration before TURP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: finasteride
Description: two weeks finasteride administration before TURP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no treatment received
Description: no treatment received before TURP
Study: NCT01836627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsufflation therapy
Description: 15 minutes twice a day of hyperinsufflation with Cough Assist® device
Study: NCT04111523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007
Description: A single dose of SY-007 or placebo injection(1mg-45mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007
Description: A single dose of SY-007 or placebo injection(1mg-45mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007
Description: A single dose of SY-007 or placebo injection(1mg-45mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007
Description: A single dose of SY-007 or placebo injection(1mg-45mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007
Description: A single dose of SY-007 or placebo injection(1mg-45mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007
Description: A single dose of SY-007 or placebo injection(1mg-45mg)
Study: NCT01305278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of Nintendo Wii Balance Gaming system
Description: Use of Nintendo Wii Balance Gaming system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of Nintendo Wii Balance Gaming system
Description: Use of Nintendo Wii Balance Gaming system
Study: NCT02507882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL28B Polymorphism
Description: SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL28B Polymorphism
Description: SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL28B Polymorphism
Description: SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
Study: NCT05523232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration training with 42 Hz
Description: Vibration exposure was given using a handheld vibration device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibration training with 63 Hz
Description: Vibration exposure was given using a handheld vibration device.
Study: NCT02018172

Intervention type: DRUG
Intervention: somatropin
Study: NCT01684982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus eluting stent
Description: experimental arm of a comparison between drug eluting stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus eluting stent
Description: control arm of a comparison between drug eluting stents
Study: NCT01120080

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Practical Counseling
Description: To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
Study: NCT02507882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: miRNA quantification
Description: RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: miRNA quantification
Description: RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: miRNA quantification
Description: RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen).
Study: NCT02796963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention
Description: The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention
Description: The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional intervention campaign
Description: The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, Community-Based Organization (CBO), and partners. These are typically designed by experts and social marketing companies.
Study: NCT03580616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Serine
Description: L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
Study: NCT05088837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: MET was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles. the limb was taken very slightly beyond the restriction barrier and was held there for 10-30 seconds, it was done 3 times per session for 12 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice and heat packs
Description: Applying 20 minutes: 10 minutes hot,10 minutes cold on sacroiliac area, 3 times per week for 12 sessions
Study: NCT04186403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Administered as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Administered as tablets.
Study: NCT03501043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport
Description: Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
Study: NCT00852670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Description: ACT-128800 administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered orally once daily
Study: NCT04632732

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test
Description: Nasal pharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test
Description: Nasal pharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test
Description: Nasal pharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test
Description: Nasal pharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test
Description: Nasal pharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 test
Description: Nasal pharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: 20cc of blood will be collected each 7 days during 28 days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: 20cc of blood will be collected each 7 days during 28 days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: 20cc of blood will be collected each 7 days during 28 days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: 20cc of blood will be collected each 7 days during 28 days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: 20cc of blood will be collected each 7 days during 28 days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: 20cc of blood will be collected each 7 days during 28 days.
Study: NCT02384655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenugreek seed meal
Description: 3x3 capsules of fenugreek seeds per day for 14 days
Study: NCT01263106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: 18-mg LY2216684 oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: 18-mg LY2216684 oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: 200-mg theophylline oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: 200-mg theophylline oral dose